Showing results (181-190 of 219) with videos related to
Sort By:
Pageof 22
Journal of Hematology & Oncology|May 17, 2017
An imprinted non-coding genomic cluster at 14q32 defines clinically relevant molecular subtypes in osteosarcoma across multiple independent datasetsKatherine E Hill, Andrew D Kelly, Marieke L Kuijjer, et al.Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 4, 2026
Phase 1 trial of pre-operative image guided intensity modulated photon radiotherapy with simultaneously integrated boost to the high-risk margin for patients with retroperitoneal sarcomaKevin X Liu, Yen-Lin Chen, Beow Y Yeap, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2025
Milademetan in advanced solid tumors with MDM2 amplification and wild-type TP53: pre-clinical and phase 2 clinical trial resultsEcaterina E Dumbrava, Thomas E Stinchcombe, Mrinal Gounder, et al.Cancer|December 29, 2015
SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcomaScott M Schuetze, J Kyle Wathen, David R Lucas, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2012
Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trialSuzanne George, Qian Wang, Michael C Heinrich, et al.Journal of Surgical Oncology|June 27, 2020
Multi-institutional analysis of stereotactic body radiotherapy for sarcoma pulmonary metastases: High rates of local control with favorable toxicityBrian C Baumann, Karen De Amorim Bernstein, Thomas F DeLaney, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 13, 2020
Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Advanced GliomaIngo K Mellinghoff, Benjamin M Ellingson, Mehdi Touat, et al.JAMA Oncology|May 1, 2018
Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to ImatinibScott M Schuetze, Vanessa Bolejack, Dafydd G Thomas, et al.Nature Medicine|January 26, 2021
Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcomaLivnat Jerby-Arnon, Cyril Neftel, Marni E Shore, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 19, 2023
Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250)Matthew Ingham, Jacob B Allred, Li Chen, et al.Pageof 22